You are here

P&T News

May 25

Xaracoll is on schedule for 2017 launch
Implanted rods offer controlled release of buprenorphine
Monoclonal antibody targets nerve growth factor
Advisors voted 7–3 against approval, but patient advocates clamor for a cure

May 24

Little is known about potential health risks
Product offers first combination of SGLT2 inhibitor and metformin
Cell-based vaccine is successor to trivalent Flucelvax
If approved, the product would be marketed by Merck

May 23

Combination product consists of Tresiba and Victoza
Entresto and Corlanor added to list of treatments
National Eye Institute report identifies trends by race, ethnicity, and gender
Decellularized vascular grafts will be studied in dialysis patients with ESRD

May 20

New sensor technology could be in clinics next year
Diazepam spray doesn’t measure up to rectal gel
Generic companies aren’t required to update safety labeling
Company revises tens of thousands of analyses
SGLT2 inhibitor is available as Invokana and Invokamet

Pages